- Home
- ALXO vs GSIW Comparison
ALXO vs GSIW Comparison
Compare ALXO & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- GSIW
- Stock Information
- Founded
- ALXO 2015
- GSIW 2016
- Country
- ALXO United States
- GSIW Hong Kong
- Employees
- ALXO N/A
- GSIW N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- GSIW
- Sector
- ALXO Health Care
- GSIW
- Exchange
- ALXO Nasdaq
- GSIW Nasdaq
- Market Cap
- ALXO 24.0M
- GSIW 27.2M
- IPO Year
- ALXO 2020
- GSIW 2023
- Fundamental
- Price
- ALXO $0.48
- GSIW $1.46
- Analyst Decision
- ALXO Strong Buy
- GSIW
- Analyst Count
- ALXO 6
- GSIW 0
- Target Price
- ALXO $3.30
- GSIW N/A
- AVG Volume (30 Days)
- ALXO 397.6K
- GSIW 915.9K
- Earning Date
- ALXO 08-07-2025
- GSIW 12-31-2024
- Dividend Yield
- ALXO N/A
- GSIW N/A
- EPS Growth
- ALXO N/A
- GSIW N/A
- EPS
- ALXO N/A
- GSIW N/A
- Revenue
- ALXO N/A
- GSIW $1,313,795.00
- Revenue This Year
- ALXO N/A
- GSIW N/A
- Revenue Next Year
- ALXO N/A
- GSIW N/A
- P/E Ratio
- ALXO N/A
- GSIW N/A
- Revenue Growth
- ALXO N/A
- GSIW N/A
- 52 Week Low
- ALXO $0.41
- GSIW $0.35
- 52 Week High
- ALXO $8.78
- GSIW $12.30
- Technical
- Relative Strength Index (RSI)
- ALXO 44.63
- GSIW 77.10
- Support Level
- ALXO $0.48
- GSIW $1.36
- Resistance Level
- ALXO $0.59
- GSIW $1.78
- Average True Range (ATR)
- ALXO 0.05
- GSIW 0.17
- MACD
- ALXO -0.00
- GSIW 0.03
- Stochastic Oscillator
- ALXO 8.75
- GSIW 69.52
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.